Navigation Links
ScandiDos Sells 100th Delta4(R) PT Unit as Adoption of Rotational Therapy Cancer Treatment Increases

CHICAGO, Nov. 3 /PRNewswire/ -- Advocate Lutheran General Hospital in the Chicago suburb of Park Ridge has chosen ScandiDos as the provider of its quality assurance (QA) solution for RapidArc(TM), and, in doing so, becomes the 100th clinical installation of Delta4. In selecting the Delta4 volumetric QA system, cancer care physicists and physicians at Advocate Lutheran General Hospital now have access to cutting edge verification of radiation therapy treatment. Key to this is the capability to perform real dose measurements and analyze the dose in the isocentric target region, the volume of greatest concern. The Delta4 system is in clinical use for IMRT, Arc therapy and TomoTherapy® since 2006 at clinics around the world.

As Advocate Lutheran General Hospital begins treating patients with RapidArc -- one form of volumetric modulated arc therapy (VMAT) or intensity modulated arc therapy (IMAT), having Delta4 for the pretreatment measurement and analysis of treatment plans will provide clinicians the comfort and confidence to proceed with these new, advanced treatments. Delta4's unique, advanced approach to measuring and presenting the dose data in three dimensions allows for quick, easy, and precise analysis of the treatment in relation to the prescription dose to the patient. Delta4's sophisticated analysis software allows the medical physicist to quickly analyze the measured dose against the treatment plan to determine the significance and cause of deviations in the dose. Because VMAT/IMAT modalities such as RapidArc by Varian Medical Systems employ many more treatment angles than conventional intensity modulated radiation therapy (IMRT), an integral part of the analysis of such is the delivery of dose from each of the actual gantry angles that will be delivered to the patient and the independent verification of each gantry angle as an element of the dose analysis. Delta4 is the only volumetric QA system on the market to perform this independent gantry angle verification, and, as such, accounts for this area of potential discrepancy as part of its measurement.

"We are very pleased that Advocate Lutheran General Hospital has chosen Delta4 PT as part of the technology solution to offer advanced radiation treatments to its patients," says Brad Dugai, National Sales Manager at ScandiDos.

"When we installed our first Delta4 in 2006, it was used to verify both IMRT and Arc Therapy treatments. Now, 3 years later, rotational therapy is becoming the new standard radiation therapy and, significantly, our 100th installed system will be used for both TomoTherapy and Varian RapidArc," says Ingemar Wiberg, VP of Sales and Marketing at ScandiDos.

Delta4 has been used by linear accelerator manufacturers in the development and validation of arc therapy treatment modalities to include Varian's RapidArc and Elekta's VMAT solution.

About ScandiDos

ScandiDos is the innovative company that introduced the new QA standard in advanced radiotherapy by moving into the era of 3D and 4D volumetric dosimetry. Founded in 2002 by a group of highly experienced physicists and engineers, ScandiDos grew out of a recognized need for practical clinical solutions for new advanced radiation therapy technologies. ScandiDos mission is to provide complete dosimetry solutions that enable clinics around the world to implement new treatment modalities satisfying the demand on accuracy in dose verification and patient through-put. ScandiDos has offices in Uppsala, Sweden and Richmond, VA, USA and is a privately held company. For more information visit

For more information, please contact:

Ingemar Wiberg, Vice President of Sales and Marketing, ScandiDos, Inc.

+46 18 472 30 31, email:

Delta4 is a registered trademark of ScandiDos AB in the United States and other countries.

RapidArc is a trademark of Varian Medical Systems.

TomoTherapy is a registered trademark of TomoTherapy, Inc.

SOURCE ScandiDos

SOURCE ScandiDos
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

2. Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System
3. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
4. Adoption of PCI in AMI Patients to Drive Drug-Eluting Stent Use
5. Frost & Sullivan Identifies Focus on Quality Management and Adoption of a Full-service Model as Keys to the Growth of the European CRO Market
6. GHX Health ConneXion(TM) Data Pool Gains Momentum as Healthcare Industry Moves Toward Standards Adoption
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Progesterone Therapy and Preterm Birth: More Evidence Helps Identify Women Who Can Benefit
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
Post Your Comments:
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... ... Comfort Keepers® of San Diego, CA is excited to announce they are ... drive cancer patients to and from their cancer treatments. Comfort Keepers provides quality ... and ongoing independence. Getting to and from medical treatments is one of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its first-ever ... Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding work ... Practice and Pediatric Emergency Medicine Practice. , “With this award, we recognize ...
Breaking Medicine News(10 mins):